TP53 and cervical carcinoma: AZD2811 treatment resulted in the loss of proliferative markers Ki67 and EdU in RB+p53 wild type HCT116 and HT1080 cells (Fig. 1B), and while there was significant reduction in Ki67 staining there was no effect on EdU incorporation in RB+p53 defective cervical cancer lines (Fig. 1C).